Publicacions en què col·labora amb Óscar María Beloqui Ruiz (22)

2011

  1. CCL20 is increased in hypercholesterolemic subjects and is upregulated by LDL in vascular smooth muscle cells: Role of NF-κB

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 31, Núm. 11, pp. 2733-2741

2010

  1. Corrigendum to "Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension" [FEBS Lett. 542 (2003) 27-31]

    FEBS Letters

  2. Serum levels of matrix metalloproteinase-10 are associated with the severity of atherosclerosis in patients with chronic kidney disease

    Kidney International, Vol. 78, Núm. 12, pp. 1275-1280

2008

  1. Asociación de marcadores inflamatorios y aterosclerosis subclínica en relación con la edad en sujetos sin enfermedad cardiovascular

    Medicina Clinica, Vol. 131, Núm. 10, pp. 361-365

  2. Association between matrix metalloproteinase-10 concentration and smoking in individuals without cardiovascular disease

    Revista Espanola de Cardiologia, Vol. 61, Núm. 12, pp. 1267-1273

2007

  1. Independent association of matrix metalloproteinase-10, cardiovascular risk factors and subclinical atherosclerosis

    Journal of Thrombosis and Haemostasis, Vol. 5, Núm. 1, pp. 91-97

  2. Metaloproteasa-10 (estromelisina-2): Un nuevo marcador de aterosclerosis subclínica

    Clinica e Investigacion en Arteriosclerosis, Vol. 19, Núm. 3, pp. 122-128

  3. Phagocytic NADPH oxidase-dependent superoxide production stimulates matrix metalloproteinase-9: Implications for human atherosclerosis

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 27, Núm. 3, pp. 587-593

2006

  1. C-reactive protein induces matrix metalloproteinase-1 and -10 in human endothelial cells: Implications for clinical and subclinical atherosclerosis

    Journal of the American College of Cardiology, Vol. 47, Núm. 7, pp. 1369-1378

  2. Ciclooxigenasa 2: ¿Una nueva diana terapéutica en la aterosclerosis?

    Medicina Clinica, Vol. 126, Núm. 20, pp. 782-786

  3. Protective effect of the G-765C COX-2 polymorphism on subclinical atherosclerosis and inflammatory markers in asymptomatic subjects with cardiovascular risk factors

    Clinica Chimica Acta, Vol. 368, Núm. 1-2, pp. 138-143

2005

  1. Independent association of von Willebrand factor with surrogate markers of atherosclerosis in middle-aged asymptomatic subjects

    Journal of Thrombosis and Haemostasis, Vol. 3, Núm. 4, pp. 662-664

  2. Monocyte cyclooxygenase-2 activity: A new therapeutic target for atherosclerosis?

    Current Drug Targets - Cardiovascular and Haematological Disorders, Vol. 5, Núm. 4, pp. 303-311

  3. Monocyte cyclooxygenase-2 overactivity: A new marker of subclinical atherosclerosis in asymptomatic subjects with cardiovascular risk factors?

    European Heart Journal, Vol. 26, Núm. 2, pp. 153-158

2004

  1. Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension

    Cardiovascular Research, Vol. 63, Núm. 1, pp. 176-185

  2. Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease

    Stroke, Vol. 35, Núm. 5, pp. 1085-1089

  3. Validation of plasma fibrinogen as a marker of carotid atherosclerosis in subjects free of clinical cardiovascular disease

    Haematologica, Vol. 89, Núm. 10, pp. 1226-1231

2003

  1. Independent association of fibrinogen with carotid intima-media thickness in asymptomatic subjects

    Cerebrovascular Diseases, Vol. 16, Núm. 4, pp. 356-362

  2. Preliminary characterisation of the promoter of the human p22phox gene: Identification of a new polymorphism associated with hypertension

    FEBS Letters, Vol. 542, Núm. 1-3, pp. 27-31

  3. The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives

    Journal of Hypertension, Vol. 21, Núm. 11, pp. 2085-2092